CL2018003158A1 - Derivados de piridinilo, composiciones farmacéuticas y sus usos como inhibidores aoc3. - Google Patents

Derivados de piridinilo, composiciones farmacéuticas y sus usos como inhibidores aoc3.

Info

Publication number
CL2018003158A1
CL2018003158A1 CL2018003158A CL2018003158A CL2018003158A1 CL 2018003158 A1 CL2018003158 A1 CL 2018003158A1 CL 2018003158 A CL2018003158 A CL 2018003158A CL 2018003158 A CL2018003158 A CL 2018003158A CL 2018003158 A1 CL2018003158 A1 CL 2018003158A1
Authority
CL
Chile
Prior art keywords
pharmaceutical compositions
pyridinyl derivatives
aoc3 inhibitors
derivatives
aoc3
Prior art date
Application number
CL2018003158A
Other languages
English (en)
Inventor
Andreas Blum
Cédrickx Godbout
Joerg P Hehn
Stefan Peters
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2018003158A1 publication Critical patent/CL2018003158A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA INVENCIÓN SE REFIERE A NUEVOS DERIVADOS DE PIRIDINILO DE LA FÓRMULA (I) EN DONDE R1 Y A SON COMO SE DEFINEN EN LA DESCRIPCIÓN Y LAS REIVINDICACIONES, A SU USO COMO MEDICAMENTOS, A LOS MÉTODOS PARA SU USO TERAPÉUTICO Y A LAS COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN.
CL2018003158A 2016-05-12 2018-11-08 Derivados de piridinilo, composiciones farmacéuticas y sus usos como inhibidores aoc3. CL2018003158A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16169356 2016-05-12

Publications (1)

Publication Number Publication Date
CL2018003158A1 true CL2018003158A1 (es) 2019-01-18

Family

ID=55967162

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003158A CL2018003158A1 (es) 2016-05-12 2018-11-08 Derivados de piridinilo, composiciones farmacéuticas y sus usos como inhibidores aoc3.

Country Status (32)

Country Link
US (1) US9926292B2 (es)
EP (1) EP3455216B1 (es)
JP (1) JP6639702B2 (es)
KR (1) KR20190003995A (es)
CN (1) CN109153664B (es)
AR (1) AR108462A1 (es)
AU (1) AU2017262707B2 (es)
CA (1) CA3023805A1 (es)
CL (1) CL2018003158A1 (es)
CO (1) CO2018012020A2 (es)
CY (1) CY1123744T1 (es)
DK (1) DK3455216T3 (es)
EA (1) EA037188B1 (es)
ES (1) ES2844926T3 (es)
HR (1) HRP20202078T1 (es)
HU (1) HUE053312T2 (es)
IL (1) IL262662B (es)
JO (1) JOP20170115B1 (es)
LT (1) LT3455216T (es)
MA (1) MA44965B1 (es)
MX (1) MX2018013701A (es)
PE (1) PE20190151A1 (es)
PH (1) PH12018502376B1 (es)
PL (1) PL3455216T3 (es)
PT (1) PT3455216T (es)
RS (1) RS61256B1 (es)
SA (1) SA518400393B1 (es)
SG (1) SG11201809687TA (es)
SI (1) SI3455216T1 (es)
TW (1) TWI746551B (es)
UA (1) UA121930C2 (es)
WO (1) WO2017194453A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019201752A1 (en) 2018-04-17 2019-10-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2020083264A1 (zh) * 2018-10-22 2020-04-30 广东东阳光药业有限公司 胍类衍生物及其用途
BR112021004635A2 (pt) * 2018-10-29 2021-05-25 Boehringer Ingelheim International Gmbh derivados de piridinil sulfonamida, composições farmacêuticas e usos das mesmas
US11472769B2 (en) 2019-10-29 2022-10-18 Eccogene (Shanghai) Co., Ltd. SSAO inhibitors and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19518073A1 (de) * 1995-05-17 1996-11-21 Hoechst Ag Substituierte Benzyloxycarbonylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
AU2004268621C1 (en) * 2003-08-29 2011-08-18 Exelixis, Inc. c-Kit modulators and methods of use
KR20070050932A (ko) * 2004-07-27 2007-05-16 가부시키가이샤 아루떼꾸 우에노 Vap―1 억제 활성을 가지는 티아졸 유도체
JP5640983B2 (ja) * 2009-09-16 2014-12-17 アステラス製薬株式会社 グリシン化合物
HUE028394T2 (en) * 2011-03-15 2016-12-28 Astellas Pharma Inc Guanidin Compound
KR20180032576A (ko) 2015-08-06 2018-03-30 우베 고산 가부시키가이샤 치환 구아니딘 유도체

Also Published As

Publication number Publication date
MX2018013701A (es) 2019-05-02
HUE053312T2 (hu) 2021-07-28
CO2018012020A2 (es) 2018-11-13
CY1123744T1 (el) 2022-05-27
PT3455216T (pt) 2021-01-18
PH12018502376A1 (en) 2019-04-08
PH12018502376B1 (en) 2019-04-08
JP2019519495A (ja) 2019-07-11
AU2017262707A1 (en) 2018-10-11
ES2844926T3 (es) 2021-07-23
JOP20170115B1 (ar) 2021-08-17
SG11201809687TA (en) 2018-11-29
WO2017194453A1 (en) 2017-11-16
TW201805278A (zh) 2018-02-16
EP3455216A1 (en) 2019-03-20
HRP20202078T1 (hr) 2021-02-19
IL262662B (en) 2021-07-29
PL3455216T3 (pl) 2021-05-17
CN109153664A (zh) 2019-01-04
MA44965B1 (fr) 2021-02-26
SI3455216T1 (sl) 2021-02-26
CN109153664B (zh) 2021-07-16
AR108462A1 (es) 2018-08-22
CA3023805A1 (en) 2017-11-16
EA037188B1 (ru) 2021-02-17
IL262662A (en) 2018-12-31
MA44965A (fr) 2019-03-20
LT3455216T (lt) 2021-01-11
AU2017262707B2 (en) 2020-11-19
JP6639702B2 (ja) 2020-02-05
DK3455216T3 (da) 2021-01-18
KR20190003995A (ko) 2019-01-10
US20170327483A1 (en) 2017-11-16
RS61256B1 (sr) 2021-01-29
NZ746586A (en) 2021-08-27
EA201892539A1 (ru) 2019-06-28
SA518400393B1 (ar) 2021-09-08
UA121930C2 (uk) 2020-08-10
PE20190151A1 (es) 2019-01-22
TWI746551B (zh) 2021-11-21
US9926292B2 (en) 2018-03-27
EP3455216B1 (en) 2020-11-04

Similar Documents

Publication Publication Date Title
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
CO2018004124A2 (es) Compuestos heterocíclicos
SV2017005514A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
UY35485A (es) Compuestos heterocíclicos y usos de los mismos
CR20150549A (es) Compuestos heterocíclicos y sus usos
DOP2018000268A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
GT201400144A (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY35467A (es) Compuestos orgánicos
UY36265A (es) “derivados de pirrolo[2,3-d]pirimidina”.
CL2018003158A1 (es) Derivados de piridinilo, composiciones farmacéuticas y sus usos como inhibidores aoc3.
CO2021005509A2 (es) Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
CL2017003107A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
CO2020007044A2 (es) Derivados de pirrol como inhibidores de acc
CL2016000597A1 (es) Derivados de desoxino jirimicina y sus métodos de uso.
UY35876A (es) Derivados de pirazolopirimidin-2-ilo como inhibidores de jak
UY35332A (es) Derivados de pirrolotriazina como inhibidores de pi3k
UY37191A (es) Derivados de dibenzofurano para uso como inhibidores de bromodominio
CO2019008110A2 (es) Activador de nrf2
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
CL2020001277A1 (es) Derivados de piridinona y su uso como inhibidores selectivos de alk-2.